These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30641100)

  • 1. Relaxin gene therapy: A promising new treatment option for various diseases with aberrant fibrosis or irregular angiogenesis.
    Hong J; Yun CO
    Mol Cell Endocrinol; 2019 May; 487():80-84. PubMed ID: 30641100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relaxin gene-knockout mouse: a model of progressive fibrosis.
    Samuel CS; Zhao C; Bathgate RA; DU XJ; Summers RJ; Amento EP; Walker LL; McBurnie M; Zhao L; Tregear GW
    Ann N Y Acad Sci; 2005 May; 1041():173-81. PubMed ID: 15956703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relaxin gene knockout mouse: a model of progressive scleroderma.
    Samuel CS; Zhao C; Yang Q; Wang H; Tian H; Tregear GW; Amento EP
    J Invest Dermatol; 2005 Oct; 125(4):692-9. PubMed ID: 16185267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single adenovirus-mediated relaxin delivery attenuates established liver fibrosis in rats.
    Kim JK; Lee JI; Paik YH; Yun CO; Chang HY; Lee SY; Lee KS
    J Gene Med; 2016; 18(1-3):16-26. PubMed ID: 26769058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis.
    Samuel CS; Zhao C; Bathgate RA; Bond CP; Burton MD; Parry LJ; Summers RJ; Tang ML; Amento EP; Tregear GW
    FASEB J; 2003 Jan; 17(1):121-3. PubMed ID: 12424226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relaxin reduces susceptibility to post-infarct atrial fibrillation in mice due to anti-fibrotic and anti-inflammatory properties.
    Beiert T; Tiyerili V; Knappe V; Effelsberg V; Linhart M; Stöckigt F; Klein S; Schierwagen R; Trebicka J; Nickenig G; Schrickel JW; Andrié RP
    Biochem Biophys Res Commun; 2017 Aug; 490(3):643-649. PubMed ID: 28634079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relaxin-1-deficient mice develop an age-related progression of renal fibrosis.
    Samuel CS; Zhao C; Bond CP; Hewitson TD; Amento EP; Summers RJ
    Kidney Int; 2004 Jun; 65(6):2054-64. PubMed ID: 15149318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis.
    Hewitson TD; Mookerjee I; Masterson R; Zhao C; Tregear GW; Becker GJ; Samuel CS
    Endocrinology; 2007 Feb; 148(2):660-9. PubMed ID: 17095590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered Relaxin as theranostic nanomedicine to diagnose and ameliorate liver cirrhosis.
    Nagórniewicz B; Mardhian DF; Booijink R; Storm G; Prakash J; Bansal R
    Nanomedicine; 2019 Apr; 17():106-118. PubMed ID: 30677498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effects of relaxin against cisplatin-induced nephrotoxicity in rats.
    Yoshida T; Kumagai H; Kohsaka T; Ikegaya N
    Nephron Exp Nephrol; 2014; 128(1-2):9-20. PubMed ID: 25403022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of relaxin on extracellular matrix remodeling in health and fibrotic disease.
    Samuel CS; Lekgabe ED; Mookerjee I
    Adv Exp Med Biol; 2007; 612():88-103. PubMed ID: 18161483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective role of relaxin in a mouse model of aristolochic acid nephropathy.
    Yang X; Thorngren D; Chen Q; Wang M; Xie X
    Biomed Pharmacother; 2019 Jul; 115():108917. PubMed ID: 31060002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relaxin as a treatment for musculoskeletal fibrosis: What we know and future directions.
    Nourmahnad A; Javad Shariyate M; Khak M; Grinstaff MW; Nazarian A; Rodriguez EK
    Biochem Pharmacol; 2024 Jul; 225():116273. PubMed ID: 38729446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relaxin ameliorates salt-sensitive hypertension and renal fibrosis.
    Yoshida T; Kumagai H; Suzuki A; Kobayashi N; Ohkawa S; Odamaki M; Kohsaka T; Yamamoto T; Ikegaya N
    Nephrol Dial Transplant; 2012 Jun; 27(6):2190-7. PubMed ID: 22086971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical profile of relaxin, a possible new drug for human use.
    Bani D; Yue SK; Bigazzi M
    Curr Drug Saf; 2009 Sep; 4(3):238-49. PubMed ID: 19534649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Recombinant Relaxin (Serelaxin) as Anti-fibrotic Agent: Pharmacology, Limitations and Actual Perspectives.
    Sassoli C; Nistri S; Chellini F; Bani D
    Curr Mol Med; 2022; 22(3):196-208. PubMed ID: 33687895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway.
    Zhou X; Chen X; Cai JJ; Chen LZ; Gong YS; Wang LX; Gao Z; Zhang HQ; Huang WJ; Zhou H
    Drug Des Devel Ther; 2015; 9():4599-611. PubMed ID: 26316699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy.
    Kim JH; Lee YS; Kim H; Huang JH; Yoon AR; Yun CO
    J Natl Cancer Inst; 2006 Oct; 98(20):1482-93. PubMed ID: 17047197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivering Relaxin Plasmid by Polymeric Metformin Lipid Nanoparticles for Liver Fibrosis Treatment.
    Li Y; Ma L; Xiong Y; Shi J; Zhang F; Chai Q; Hu G; Liu Y
    Curr Drug Deliv; 2024; 21(3):431-437. PubMed ID: 37032506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus-relaxin gene therapy for keloids: implication for reversing pathological fibrosis.
    Lee WJ; Kim YO; Choi IK; Rah DK; Yun CO
    Br J Dermatol; 2011 Sep; 165(3):673-7. PubMed ID: 21623756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.